N8‐GP (turoctocog alfa pegol) is a glycoPEGylated, extended half‐life human recombinant factor VIII (FVIII) shown to be an efficacious treatment for patients with haemophilia A. Accurate monitoring of replacement therapy helps ensure proper dosing, leading to better patient care. Here, F8 is linked to hemophilia A.